Citations

Clear

23 citation(s) found for "Shen, K Robert".

Are lobectomy and neoadjuvant therapy the missing link in improving early-stage small cell lung cancer survival?
Alwatari, Yahya, Vierkant, Robert A., Saddoughi, Sahar, Tapias, Luís Felipe, Shen, Robert, Cassivi, Stephen D. , Wigle, Dennis A., Reisenauer, Janani , Puig, Carlos, Alwatari, Yahya , Vierkant, Robert A., Shanshal, Mohamed , Saddoughi, Sahar A. , Shen, Robert K. , Wigle, Dennis A. , Puig, Carlos A.

Mayo Clinic

Journal of Clinical Oncology | May 28, 2026 | Volume: 44 | Issue: 16_suppl | Pages: 8077-8077

10.1200/jco.2026.44.16_suppl.8077 Get It

8077 Background: Small cell lung cancer (SCLC) is an aggressive malignancy with poor prognosis. This study evaluates national trends in surgical management of early-stage SCLC using the National Cancer Database (NCDB), aiming to identify factors associated with improved outcomes and assess the survival benefit of surgical resection. Methods: Patients diagnosed with clinical stage T1–T3 N0 M0 SCLC between 2004 and 2022 were identified from the NCDB. Exclusions included non-SCLC histologies, advanced or missing staging, non-lobectomy surgeries, and incomplete survival data. Propensity score matching (1:1) was used to balance surgical and non-surgical cohorts based on demographic, clinical, and socioeconomic variables. Kaplan-Meier and Cox regression analyses were used to evaluate overall survival, stratified by T stage. Results: Among 17,762 patients with early-stage SCLC, 3,234 (18.2%) underwent lobectomy with mediastinal lymph node dissection. Surgical rates increased from 5% in 2004, 17% in 2013 to 24% in 2021. Surgery was more common in T1 (26.5%) than T2 (11.4%) or T3 (4.6%) disease. After matching, surgery was associated with improved survival across all T stages, with no significant interaction between T stage and surgical benefit (p=0.43). Older age, male sex, and higher comorbidity scores predicted worse outcomes. Among surgical patients, 2.3% received neoadjuvant therapy and 71.6% received adjuvant treatment. Systemic therapy-both neoadjuvant (HR 0.63) and adjuvant (HR 0.69)-was significantly associated with improved survival. Conclusions: Lobectomy remains underutilized in early-stage SCLC but is linked to significantly improved survival. Albeit small patient's number, neoadjuvant systemic therapy further enhanced survival, supporting broader use of surgery and multimodal treatment in appropriately selected patients Univariable results 1 Multivariable results 2 Characteristic No. deaths Person-months HR (95% CI) p-value HR (95% CI) p-value Charlson score <0.001 <0.001 0 761 77727 1.00 (ref) 1.00 (ref) 1 623 60483 1.06 (0.95,1.18) 1.07 (0.96,1.20) 2 or more 350 27025 1.30 (1.15,1.48) 1.30 (1.13,1.48) Clinical T-stage 0.011 0.014 cT1N0M0 1266 124916 1.00 (ref) 1.00 (ref) cT2N0M0 406 33924 1.18 (1.06,1.32) 1.20 (1.06,1.35) cT3N0M0 62 6393 0.96 (0.75,1.24) 1.00 (0.76,1.31) Residual disease <0.001 <0.001 No residual tumor 1626 158838 1.00 (ref) 1.00 (ref) Residual tumor 92 4699 1.91 (1.55,2.36) 1.91 (1.52,2.40) Neoadjuvant systemic treatment 0.253 0.034 No 1629 154116 1.00 (ref) 1.00 (ref) Yes 30 3495 0.81 (0.56,1.16) 0.63 (0.41,0.97) Adjuvant radiation 0.067 <0.001 No 1209 118925 1.00 (ref) 1.00 (ref) Yes 452 40471 1.11 (0.99,1.23) 1.33 (1.18,1.51) Adjuvant systemic treatment <0.001 <0.001 No 563 44045 1.00 (ref) 1.00 (ref) Yes 1096 113566 0.75 (0.68,0.83) 0.69 (0.62,0.78)
Impact of sarcopenia on short- and long-term outcomes after multimodal therapy for esophageal cancer.
Anyeti-Anum, Grace Patrice, Ortiz, Belisario A, Hartman, Robert P. , Harmsen, William S. , Hallemeier, Christopher L. , Krishan, Jethwa, Yoon, Harry H. , Jin, Zhaoui, Zhu, Mojun , Reisenauer, Janani , Cassivi, Stephen David, Wigle, D., Tapias, Luís Felipe, Santore, Lee Ann , Chaar, Mohamad K. Abou , Anyetei-Anum, Grace Patrice , Hallemeier, Christopher Leigh , Puig, Carlos A. , Cassivi, Stephen D. , Shen, Robert K. , Wigle, Dennis A.

Mayo Clinic

Journal of Clinical Oncology | January 12, 2026 | Volume: 44 | Issue: 2_suppl | Pages: 334-334

10.1200/jco.2026.44.2_suppl.334 Get It

334 Background: Sarcopenia, or decreased skeletal muscle mass, has been associated with worse surgical and oncologic outcomes across multiple malignancies. This study investigates the impact of sarcopenia on outcomes after multimodal therapy for esophageal cancer. Methods: Retrospective observational cohort study including adult patients who underwent neoadjuvant therapy followed by esophagectomy for primary esophageal cancer from January 2000 - December 2021. A fully automated abdominal segmentation using deep convolutional neural network was utilized to calculate skeletal muscle index (SMI) from preoperative CT scans performed at our institution. Males with SMI <52.4 cm 2 /m 2 and females with SMI <38.5 cm 2 /m 2 at any point before surgery were classified as sarcopenic. The relationship between sarcopenia and patient demographics, operative details, and complications were explored using chi-square tests. The relationship between sarcopenia and disease-free survival and overall survival were investigated using parsimonious multivariable analysis retaining variables with p-value <0.05 using backward selection method. Results: We identified 200 patients meeting the study criteria with 142 (71%) having sarcopenia at any time prior to surgery. Patients with sarcopenia were significantly older [65.2 (59.6, 71.2) vs 63 (53.6, 67.5), p = .023] and more likely to have had open surgery [129 (90.8%) vs 46 (79.3%), p = .034]. There were no significant differences in sex, history of diabetes, coronary artery disease, renal disease, smoking, cancer type, cancer stage, tumor size, tumor location, or margin status between sarcopenic groups ( p > .05). Sarcopenic patients were significantly more likely to require blood transfusion ≥3 units after esophagectomy [79 (55.6%) vs 8 (13.8%), p < .001] or to experience complications requiring surgical intervention [36 (24.6%) vs 7 (12.1%), p = .048]. Multivariate analysis revealed that sarcopenia was associated with disease-free and overall survival (Table). Conclusions: Sarcopenia is a prognostic factor in patients undergoing multimodal therapy for esophageal cancer. Interventions that aim to prevent decreases in SMI after initiating neoadjuvant therapy should be investigated. Multivariate analysis with sarcopenia predicting outcomes. Disease free survivalHR (95% CI) p-value Overall survivalHR (95% CI) p-value Age 1.04 (1.02, 1.06) < .001 1.04 (1.02, 1.07) < .001 Epicenter Middle Upper 1.88 (1.21, 2.86)3.16 (1.67, 5.98) .001.005< .001 1.96 (1.26, 3.04)4.00 (1.90, 8.44) < .001.003< .001 Stage Stage II Stage III Stage IV 1.88 (0.95, 3.71)2.90 (1.46, 5.75)16.02 (6.12, 41.93) < .001.069.002< .001 1.65 (0.83, 3.25)2.76 (1.37, 5.55)10.14 (4.03, 25.53) < .001.151.005< .001 Cancer type - - 1.76 (1.03, 3.02) .039 Transfusion > 3 pRBC - - 1.54 (0.99, 2.40) .057 BMI prior to cancer diagnosis - - 0.98 (0.94, 1.01 .208 Sarcopenic 1.76 (1.16, 2.67) .007 1.64 (1.04, 2.60) .033
Tissue regenerative medicine: Clinical advances, challenges, and opportunities
Badawy, Seleem , Gopinath, Varshiny , Espinosa, Ana M. Diaz , Kelmser, Ethan C., Duke, Victoria R. , Kamaraju, Veda , Nakayama, Karina, Manna, Manoj , Liu, Julianne J-Y , Shen, K. Robert , Suthiwanich, Kasinan , Duke, Victoria , Kamaraju, Veda , Manna, Manoj , Liu, Julianne J-Y , Nunes, Sara S , Shen, Keyue , Huang, Ngan F , Diaz Espinosa, Ana M , Badawy, Seleem , Gopinath, Varshiny , Suthiwanich, Kasinan , Kelmser, Ethan C, Nakayama, Karina

Mayo Clinic

APL Bioengineering | December 18, 2025 | Volume: 9 | Issue: 4 | Pages: No page available

10.1063/5.0296897 | PMID 41424914 Get It

Regenerative medicine is transforming how we restore tissue function, leveraging advances in cell and molecular biology, biomaterials, and engineered microenvironments. While there have been notable advances and rapid progress over the past few decades, ongoing challenges persist in the technical development and effective translation of these advancements to clinical care. This perspective highlights clinically promising examples and critically assesses present challenges in translating tissue regenerative medicine therapies from the bench to the clinic. We further examine the evolving landscape of regenerative medicine by describing strategies to optimize the cellular microenvironment, the impact of patient demographics, and the use of artificial intelligence to shape the future of this field.
Diaphragmatic rupture due to massive gastric volvulus after robotic-assisted diaphragm plication
Gregorio, Anthony M De , Shen, K. Robert , De Gregorio, Anthony M , Tapias, Luis F.

Mayo Clinic

Journal of Surgical Case Reports | September 13, 2024 | Volume: 2024 | Issue: 9 | Pages: No page available

10.1093/jscr/rjae546 | PMID 39267910 Get It

Abstract Gastric volvulus has been rarely associated with diaphragmatic paralysis or eventration. In this article, we present the case of a patient with idiopathic paralysis of the left hemidiaphragm that underwent treatment with a robotic thoracoscopic diaphragm plication, which was complicated by massive gastric volvulus resulting in such significant intra-abdominal hypertension that the ipsilateral diaphragm ruptured anterior to the plication suture line.
Cost analysis of targeted and immunotherapies in operable esophageal and non-small cell lung cancers.
Alwatari, Yahya , Shanshal, Mohamed , Johnson, Nate C., Thao, Viengneesee , Borah, Bijan J. , Shen, Robert K.

Mayo Clinic

Journal of Clinical Oncology | June 28, 2024 | Volume: 42 | Issue: 16_suppl | Pages: 8051-8051

10.1200/jco.2024.42.16_suppl.8051 Get It

8051 Background: The National Comprehensive Cancer Network (NCCN) currently recommends the use of Atezolizumab, Nivolumab, Osimertinib, and Pembrolizumab in the perioperative management of non-small cell lung cancers (NSCLC) and esophageal cancers (EC). As the therapeutic landscape evolves, we aim to evaluate the cost implications of these guidelines for eligible patients in the United States. Methods: The Medicare Part B payment allowance limits of each medication were ascertained except Osimertinib for which an approximate wholesale acquisition cost (WAC) was reported due to privately administered Medicare Part D coverage. Using national data and published literature, we estimated the annual incidence of patients with newly diagnosed EC and NSCLC who would be eligible for surgery combined with neoadjuvant and/or adjuvant immune and targeted therapy. We applied the estimated cost of the medication based on dosing and duration of treatment, which spanned 1 year for all but adjuvant Osimertinib, which spanned 3 years. Using these data, the cost per patient and the total cost for an incident cohort were estimated. Results: We estimated that 8,602 patients with newly diagnosed EC would be eligible for adjuvant Nivolumab; the cost to treat one patient was $248,529, and the cost to treat one incident cohort was approximately $2 billion (Table). We estimated that 50,409 patients with NSCLC will meet the criteria for neoadjuvant Nivolumab with a total cost of three cycles of $32,894 per patient and $1.7 billion per cohort. Among NSCLC patients who may undergo resection and qualify for adjuvant therapy (Stage IB – IIA with high-risk features or IIB-IIIA), 85,063 patients are anticipated to be EGFR-negative and treated with adjuvant Atezolizumab or Pembrolizumab. Treatment costs range from $178,584 – $197,320 per patient with up to $16 billion cost per cohort. The cost to treat one patient with adjuvant Osimertinib was $556,720, and the cost to treat one incident cohort was close to $10 billion. In total, the cost to treat an incident cohort of eligible operable thoracic malignancies could exceed $30 billion. Conclusions: Neoadjuvant and adjuvant immune and targeted therapy in operable thoracic patients is associated with a significant cost burden. Prospective large-scale studies are needed to assess cost-effectiveness, particularly given the paucity of superior overall survival data with these agents. [Table: see text]
Occult Lung Cancer–Associated Autoimmune Encephalitis Presenting as Acute Psychosis
McCarter, Shelly K, Shen, K Robert , Wylam, Mark E. , E Wylam, Mark

Mayo Clinic

Military Medicine | March 30, 2024 | Volume: 189 | Issue: 7-8 | Pages: e1813-e1818

10.1093/milmed/usae116 | PMID 38554268 Get It

ABSTRACT During deployment, a 52-year-old male developed acute behavioral changes. Though initially considered to have PTSD and related agitation and confusional state, his evaluation was consistent with acute encephalopathy. Magnetic resonance imaging of the brain showed T2 hyperintensities, and CSF analysis was positive for anti-N-methyl-D-aspartate receptor antibody. A nuclear protein in testis carcinoma midline carcinoma was discovered in the lung. Immunotherapy and surgical resection led to steady improvement prior to adjuvant chemotherapy. Autoimmune encephalitis due to anti-N-methyl-D-aspartate receptor antibodies is increasingly being recognized as causal of acute behavioral change.
Prognostic factors in resected pulmonary carcinoid tumors: A retrospective study with 10 years of follow‑up
Du, Lin , Ernani, Vinicius , Jaroszewski, Dawn E. , Cassivi, Steven D., Beamer, Staci E. , Santos, Pedro Reck dos , Wigle, Dennis A. , Sun, Daqiang , Shen, K. Robert , Liu, Alex, Schild, Steven E. , Luo, Yung-Hung, Wampfler, Jason A. , Santos, Pedro A. Reck dos, Wigle, Dennis, Santos, Pedro Augusto Reck Dos , Liu, Alex C.H. , Luo, Yung‐Hung , Yang, Ping

Mayo Clinic

Oncology Letters | January 10, 2023 | Volume: 25 | Issue: 2 | Pages: No page available

10.3892/ol.2023.13666 | PMID 36742364 Get It

A Comparison of Negative Pressure and Conventional Therapy in Infected Open Chest Wounds
Thomas, Mathew , Makey, Ian A. , Buchanan, Mauricia A., White, Launia J. , Lechtenberg, Bettie J., Wigle, Dennis A. , Shen, K. Robert , Thomas, Mathew , Wigle, Dennis, Blackmon, Shanda H, Thomas, Mathew , Heckman, Michael G. , Blackmon, Shanda

Mayo Clinic

Surgical Infections | May 27, 2021 | Volume: 22 | Issue: 9 | Pages: 955-961

10.1089/sur.2020.397 | PMID 34042543 Get It

Reply: Muscle Flap Transposition for the Management of Intrathoracic Fistulas
Shen, K. Robert , Moran, Steven L.

Mayo Clinic

Plastic & Reconstructive Surgery | April 21, 2021 | Volume: 147 | Issue: 5 | Pages: 896e-897e

10.1097/prs.0000000000007835 | PMID 33878061 Get It

HER2-overexpression/amplification and survival in patients with resectable esophageal/gastroesophageal junction adenocarcinoma (E/GEJ-AC) treated with neoadjuvant carboplatin/paclitaxel-based chemoradiation.
Feng, Yening , Condell, Cristobal Tomas Sanhueza, Hallemeier, Christopher L. , Hobday, Timothy J. , Cassivi, Stephen D. , Neben-Wittich, M.A. , Nichols, Francis C., Merrell, Kenneth W. , Blanco, Ellen W., Pitot, Henry C., Jatoi, Aminah , Haddock, Michael G. , Wigle, Dennis A. , Yoon, Harry H. , Hallemeier, Christopher Leigh , Blackmon, Shanda , Hubbard, Joleen M. , Hálfdánarson, Þorvarður R. , Shen, Robert K. , McWilliams, Robert R. , Alberts, Steven R.

Mayo Clinic

Journal of Clinical Oncology | January 22, 2021 | Volume: 39 | Issue: 3_suppl | Pages: 239-239

10.1200/jco.2021.39.3_suppl.239 Get It

239 Background: After trastuzumab (T) approval for advanced HER2-positive E/GEJ-AC, HER2 testing has increased in patients (pts) with resectable disease. Neoadjuvant carboplatin/paclitaxel chemoradiation (nCP-CRT) is a common therapy approach. We performed the largest evaluation, to our knowledge, of the prognostic impact of HER2 in E/GEJ-AC pts treated with nCP-CRT. Methods: We retrospectively reviewed medical records of all trimodality-eligible (T2+ or N+) pts with E/GEJ-AC who started nCP-CRT (usually 50.4 Gy) with planned surgery at Mayo Clinic (2014-2019). HER2 was tested using standard criteria for HER2 positivity (ie, immunohistochemistry 3+ or amplification by in situ hybridization). Clinicopathologic data and time to recurrence (TTR), disease free survival (DFS), overall survival (OS), survival after recurrence (SAR), and pathologic complete response (pCR – ie, no residual tumor in primary or nodes) were collected. Kaplan Meier and multivariate Cox analysis were used. Results: Of 161 consecutive eligible pts, HER2 status was available in 107 pts (HER2-positive n=26, HER2-negative n=81) of whom n=82 had surgery and n=19 had pCR. Most tumors were clinical T3 (80%) or N+ (81%), histologic grade 3 of 3 (62%). HER2 positivity was significantly associated with lower grade, but not with age, clinical T or N, or ECOG performance status (PS). A similar proportion of HER2-positive ( vs negative) pts had surgery. Among pts who had surgery, pCR rates were lower in HER2-positive ( vs negative) pts (11% [2/19] vs 27% [17/63]). After a median follow up of 23 mo, DFS and TTR were significantly shorter in HER2 positive ( vs negative) pts, independent of other pretreatment covariables (Table). Yet OS was comparable. Lung recurrence was enriched in HER2 positive ( vs negative) pts. Among pts with recurrence, SAR was longer in HER2-positive vs -negative pts. A total of 53% (10/19) of previously HER2-positive pts received T-based therapy after recurrence, and these pts were the drivers of favorable SAR (median 22 mo in n=10 HER2-positive pts who received T vs 11 mo in n=9 HER2-positive pts who did not receive T vs 11 mo in n=40 HER2-negative pts; P log-rank=.01). Conclusions: HER2 positivity ( vs negativity) is independently associated with shorter TTR and DFS, but more comparable OS. The adverse association of HER2 on tumor response and TTR may have been largely overcome through enhanced survival after recurrence, although OS data are maturing. These data may have implications for the design of endpoints in future curative-intent anti-HER2 trials. [Table: see text]